To investigate the efficacy of hydromorphone via intravenous patient-controlled analgesia (IV PCA) for PHN management.
Postherpetic neuralgia (PHN) is the most common problem of
acute herpes zoster with many patients still facing unbearable pain conditions.
This randomized controlled trial supported the use of hydromorphone IV PCA
plus oral pregabalin for pain relief due to PHN.
To investigate the efficacy of hydromorphone via intravenous
patient-controlled analgesia (IV PCA)
for PHN management.
Total 201 patients were divided into two
groups as:
Efficacy was assessed at 1 week, 4 weeks, and
12 weeks follow-up.
As compared to control group, the patients in the
hydromorphone group had a significantly lower numerical rating scale (NRS)
score, and the difference of NRS scores between the these groups was
statistically significant at 4 weeks and 12 weeks following the therapy.
Occurrence of breakthrough pain in the hydromorphone group was significantly
lower than control group at 1 week and 4 weeks. Also, an improved sleep quality
was observed in hydromorphone group. Dizziness and nausea were commonly
reported advserse events.
Combination of hydromorphone IV PCA and oral
pregabalin offers superior pain relief in PHN patients.
The Korean Journal of Pain
Intravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: a multicenter, randomized controlled study
Ying Huang et al.
Comments (0)